Stock BINV BIOINVENT INTERNATIONAL AB
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases BioInvent International AB

Equities

BINV

SE0015244520

Real-time Estimate Cboe Europe
Other stock markets
 14:22:37 07/05/2024 BST 		5-day change 1st Jan Change
26.42 SEK -2.13% Intraday chart for BioInvent International AB +1.73% +39.50%
05-03 Bioinvent International AB Resolves to Elect Laura Lassouw-Polman as New Board Member CI
04-30 BioInvent Announces Evaluating Attana Technology CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Resolutions at BioInvent's Annual General Meeting 2024
AQ
BioInvent International : Resolutions at BioInvent's Annual General Meeting 2024
PU
Resolutions at BioInvent’s Annual General Meeting 2024
AQ
BioInvent evaluating Attana Technology
AQ
BioStock: BioInvent selected to present at ASCO in Chicago
AQ
BioInvent International AB, Interim report January-March 2024
AQ
BioInvent Q1 2024 - Approaching Catalysts
AQ
BioInvent to Present Clinical Data from its two leading assets at ASCO 2024
AQ
BioInvent International AB: Interim report January-March 2024
AQ
BioInvent International AB publishes Annual Report 2023
AQ
BioStock: BioInvent deepens collaboration with MSD
AQ
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company s second anti-TNFR2 antibody in combination with KEYTRUDA
AQ
BioInvent International : announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)
PU
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)
AQ
Notice to Annual General Meeting in BioInvent International AB
AQ
BioStock: BioInvent's CEO comments on the study success in China
AQ
BioInvent International, CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed, Refractory Indolent Non-Hodgkin's Lymphoma In China
AQ
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
PU
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China
AQ
BioInvent International AB Year-end report January 1, December 31, 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BINV Stock
  4. News BioInvent International AB
  5. Press Releases